All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?

The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena Buckstein, and featured Theo de Witte, Silvia Magalhães, and Yasushi Miyazaki. The topic of this discussion, “What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?”, was identified as an unmet educational need within MDS treatment.

 

What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?

Buckstein begins by discussing two case studies, and the use of IPSS-R to define risk. De Witte talks about the effect that comorbidities can have on patient outcomes, and the committee discusses the treatment options and possible outcomes of the case study patients. Buckstein presents information on prognostic factors and the significance of mutations in prognosis. The committee also discusses how to calculate prognostic factors to decide treatment strategies, determine survival, and counsel patients. Buckstein then explains which genes are included in the IPSS-Molecular (IPSS-M) calculations. Finally, the committee discusses how the IPSS-M could be implemented in clinical settings, including potential problems.